Drug Profile
Gallium-68 RM2 - Life Moleuclar Imaging
Alternative Names: 68Ga-Bombesin; [(68)Ga]-labelled bombesin; [68GA]DOTA-4-AMINO-1-CARBOXYMETHYLPIPERIDINE-D-PHE-GLN-TRP-ALA-VAL-GLY-HIS-STA-LEU-NH2; [68Ga]RM2; BAY 867548; Bombesin (68Ga) labelled; Gallium-68-bombesinLatest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer Life Molecular Imaging; National Cancer Institute (USA); Stanford University; University Hospital of Bordeaux
- Class Imaging agents; Neuropeptides; Oligopeptides; Organometallic compounds; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Bombesin receptor antagonists; Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 07 Mar 2022 Stanford University in collaboration with General electric completes a phase I/II trial in Prostate cancer (Diagnosis) in the US (IV) (NCT03949517)
- 05 Mar 2021 Phase-II development is ongoing in France and USA (IV)
- 29 May 2020 Efficacy and pharmacodynamics data from a phase II/III trial in Prostate cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASC0-2020)